One study evaluated the expression of PD‐L2 in a mixed group of patients diagnosed with renal cell carcinoma (N = 59), melanoma (N = 38), metastatic urothelial carcinoma (N = 251), and NSCLC (N = 112). This evidence concerns the gene PDCD1LG2 and melanoma.